Exercise and Nutritional Intervention in Older Adults With Sarcopenia (Spleen-Kidney Deficiency Pattern)

November 10, 2026 updated by: Fenghua Qian, Shanghai Yueyang Integrated Medicine Hospital

A Prospective Single-Arm Cohort Study of Exercise and Nutritional Intervention in Older Adults With Sarcopenia (Spleen-Kidney Deficiency Pattern)

This study will enroll older adults with sarcopenia (Spleen-Kidney Deficiency Pattern) who will receive exercise and nutritional interventions. By assessing changes from baseline in DXA-measured appendicular muscle mass and other efficacy outcomes, the study aims to characterize the longitudinal changes in sarcopenia over a 24-week period and provide an external control for a future randomized, double-blind clinical trial of Peiyuan Guben Tongluo Ointment in older adults with sarcopenia (Spleen-Kidney Deficiency Pattern).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xiao ya Zhang, Undergraduate
  • Phone Number: +86 13645337890
  • Email: 2365672026@qq.com

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200437
        • Recruiting
        • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients aged ≥ 60 and ≤ 90 years, regardless of sex.
  2. Meet the diagnostic criteria for sarcopenia in older adults according to both Western medicine and traditional Chinese medicine (TCM).
  3. Meet the TCM diagnostic criteria for the Spleen-Kidney Deficiency Pattern.
  4. Be willing to comply with the study intervention protocol, attend scheduled follow-up visits, and provide written informed consent.

Exclusion Criteria:

  1. Patients with severe cerebrovascular diseases resulting in quadriplegia, long-term bedridden status, or complete loss of muscle strength (Grade 0); patients with muscle atrophy caused by various factors; or those unable to perform activities of daily living independently.
  2. Patients with Alzheimer's disease or vascular dementia accompanied by impaired consciousness, aphasia, delirium, inability to communicate or respond appropriately, or disorientation to time, place, or person.
  3. Patients with severe psychiatric disorders or depressive conditions who are receiving relevant pharmacological treatment.
  4. Patients with comorbid conditions that may affect nutritional status, including malignancies, severe infections, gastrointestinal bleeding, hepatic or renal insufficiency, or cardiac insufficiency.
  5. Patients who have received or are currently receiving traditional Chinese medicine treatment within the past month, or who have received medications affecting muscle contraction or relaxation within the past month.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
DXA-measured appendicular skeletal muscle mass
Time Frame: Baseline, week 12, week 24

Detected by dual-energy X-ray absorptiometry (GE Healthcare, DXA). The skeletal muscle mass index (SMI) is defined as the ratio of DXA-measured skeletal muscle mass to the square of height.

Baseline, week 12, week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upper limb handgrip strength
Time Frame: Up to 24 weeks

Use a hand dynamometer to record grip strength data for comparison.

Up to 24 weeks
Handgrip strength
Time Frame: Baseline, week 12, week 24

Use a hand dynamometer to record grip strength data for comparison.

Baseline, week 12, week 24
Timed Up and Go test (TUG)
Time Frame: Baseline, week 12, week 24

Subjects shall sit on a chair with a seat height of 46 cm, a straight backrest and armrests (armrest height approximately 65 cm). They are required to stand up with minimal assistance from the armrests. The total time is recorded from leaving the backrest to standing upright, walking 3 meters at their usual walking speed, turning around, walking back, and sitting down fully against the chair back. The average value of three trials is calculated. Elderly individuals who routinely use walking aids may use them during the test.

Baseline, week 12, week 24
Berg Balance Scale (BBS)
Time Frame: Baseline, week 12, week 24

The scale consists of 14 items in total, including sitting to standing, standing to sitting, standing unsupported, standing with eyes closed, reaching forward with outstretched arms, turning 360 degrees, alternating foot placement on a step, single-leg standing, etc. All items take 10-15 minutes to complete. Each item is scored from a minimum of 0 points to a maximum of 4 points, with a total possible score of 56 points. A higher score indicates better balance function; a score below 40 points suggests an increased risk of falls.

Baseline, week 12, week 24
TCM Syndrome Score
Time Frame: Baseline, week 12, week 24

In accordance with the scoring criteria specified in the 《Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs》, the total score for **Spleen-Kidney Deficiency Syndrome** was calculated.

Baseline, week 12, week 24
Mini Nutritional Assessment (MNA)
Time Frame: Baseline, week 12, week 24

Nutritional status was evaluated using the Mini Nutritional Assessment (MNA). This scale comprehensively evaluates an individual's nutritional status through a series of questions covering body weight, dietary intake, mobility, mental state and other aspects. The full score of the scale is 30 points. Grading criteria: a total score ≥ 24 indicates good nutritional status; a score between 17 and 24 suggests risk of malnutrition; a total score below 17 confirms definite malnutrition.

Baseline, week 12, week 24
Activities of Daily Living (ADL) Scale
Time Frame: Baseline. week 12, week 24

The Activities of Daily Living (ADL) scale, developed by American scholars Lawton and Brody in 1969, is a medical assessment tool composed of the Physical Self-Maintenance Scale (PSMS) and the Instrumental Activities of Daily Living (IADL). It is mainly used to evaluate subjects' functional levels in basic living skills such as feeding, dressing and mobility, as well as the ability to use instrumental tools. Constructed from two dimensions including PSMS and IADL, the scale contains a total of 10 assessment items.

Baseline. week 12, week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fenghua Qian, Undergraduate, Shanghai Yueyang Integrated Medicine Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 17, 2026

Primary Completion (Estimated)

April 15, 2027

Study Completion (Estimated)

October 15, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe